Covered recipient · General Payments record
DILEEP PUPPALA
Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$17,360.76
155 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $13,196.00 | 8 |
| Food and Beverage | $3,362.77 | 143 |
| Consulting Fee | $722.00 | 1 |
| Education | $79.99 | 3 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| GlaxoSmithKline, LLC. | $9,963.22 | 25 |
| GENZYME CORPORATION | $2,968.03 | 9 |
| Regeneron Healthcare Solutions, Inc. | $1,167.90 | 6 |
| Mylan Specialty L.P. | $795.18 | 6 |
| AstraZeneca Pharmaceuticals LP | $430.33 | 19 |
| Actelion Pharmaceuticals US, Inc. | $393.10 | 12 |
| JAZZ PHARMACEUTICALS INC. | $255.50 | 15 |
| United Therapeutics Corporation | $225.67 | 8 |
| Insmed, Inc. | $204.56 | 7 |
| HARMONY BIOSCIENCES LLC | $156.29 | 11 |
| Mallinckrodt Hospital Products Inc. | $115.93 | 5 |
| Ethicon US, LLC | $113.00 | 1 |
| Janssen Pharmaceuticals, Inc | $103.08 | 6 |
| Optinose US, Inc. | $93.42 | 4 |
| AbbVie Inc. | $74.24 | 4 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $67.74 | 4 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $47.74 | 3 |
| Octapharma USA, Inc. | $33.31 | 1 |
| Chiesi USA, Inc. | $33.29 | 2 |
| Amgen Inc. | $29.00 | 1 |
| E.R. Squibb & Sons, L.L.C. | $25.35 | 2 |
| PFIZER INC. | $20.83 | 1 |
| Philips Electronics North America Corporation | $17.42 | 1 |
| Merck Sharp & Dohme Corporation | $14.29 | 1 |
| Grifols USA, LLC | $12.34 | 1 |
Page 2 of 4; records 51–100 of 155 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
DILEEP PUPPALA
NPI 1215989900 · CMS profile ID 282497
Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease
HOUSTON, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 4; records 51–100 of 155 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1215989900?year=2021&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- DILEEP PUPPALA, NPI 1215989900, CMS profile ID 282497. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 155 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1215989900?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). DILEEP PUPPALA, NPI 1215989900, CMS profile ID 282497. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 155 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1215989900?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- DILEEP PUPPALA, NPI 1215989900, CMS profile ID 282497, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 155 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1215989900?year=2021&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
155 matching records · $17,360.76 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 155.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Octapharma USA, Inc. | $33.31 | 09/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812975693 | CMS |
| Optinose US, Inc. | $23.84 | 09/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851673217 | CMS |
| GlaxoSmithKline, LLC. | $4.82 | 09/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802254835 | CMS |
| GlaxoSmithKline, LLC. | $13.57 | 08/31/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802504873 | CMS |
| Chiesi USA, Inc. | $15.98 | 08/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849057363 | CMS |
| Actelion Pharmaceuticals US, Inc. | $22.93 | 08/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788002823 | CMS |
| GlaxoSmithKline, LLC. | $1,800.00 | 08/19/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 803101653 | CMS |
| AbbVie Inc. | $15.89 | 08/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795722567 | CMS |
| Regeneron Healthcare Solutions, Inc. | $992.00 | 08/17/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809615433 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $12.19 | 08/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763465126 | CMS |
| GENZYME CORPORATION | $17.51 | 08/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843550189 | CMS |
| JAZZ PHARMACEUTICALS INC. | $12.46 | 08/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845617443 | CMS |
| Regeneron Healthcare Solutions, Inc. | $17.33 | 08/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809615431 | CMS |
| GlaxoSmithKline, LLC. | $14.84 | 08/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 803107471 | CMS |
| Janssen Pharmaceuticals, Inc | $14.08 | 08/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788002813 | CMS |
| Chiesi USA, Inc. | $17.31 | 08/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849050435 | CMS |
| JAZZ PHARMACEUTICALS INC. | $10.65 | 08/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845617441 | CMS |
| GlaxoSmithKline, LLC. | $3.23 | 07/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802791687 | CMS |
| HARMONY BIOSCIENCES LLC | $21.49 | 07/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 853086049 | CMS |
| JAZZ PHARMACEUTICALS INC. | $22.88 | 07/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845617439 | CMS |
| AstraZeneca Pharmaceuticals LP | $18.22 | 07/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834329091 | CMS |
| AstraZeneca Pharmaceuticals LP | $23.24 | 07/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834354265 | CMS |
| Grifols USA, LLC | $12.34 | 07/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 846764961 | CMS |
| JAZZ PHARMACEUTICALS INC. | $18.38 | 07/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845617445 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.20 | 07/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834348963 | CMS |
| Insmed, Inc. | $23.55 | 07/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851726417 | CMS |
| HARMONY BIOSCIENCES LLC | $12.33 | 07/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 853086041 | CMS |
| Mallinckrodt Hospital Products Inc. | $12.13 | 07/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845375011 | CMS |
| Mallinckrodt Hospital Products Inc. | $31.49 | 07/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845375009 | CMS |
| Actelion Pharmaceuticals US, Inc. | $28.60 | 07/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788002841 | CMS |
| United Therapeutics Corporation | $21.88 | 07/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 839133025 | CMS |
| United Therapeutics Corporation | $21.88 | 07/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 839133027 | CMS |
| GENZYME CORPORATION | $17.25 | 07/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843550187 | CMS |
| Janssen Pharmaceuticals, Inc | $17.30 | 07/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788002815 | CMS |
| GlaxoSmithKline, LLC. | $3,600.00 | 07/01/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802017853 | CMS |
| Regeneron Healthcare Solutions, Inc. | $17.63 | 07/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809615429 | CMS |
| HARMONY BIOSCIENCES LLC | $23.29 | 06/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 853086039 | CMS |
| United Therapeutics Corporation | $107.69 | 06/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 839136487 | CMS |
| Regeneron Healthcare Solutions, Inc. | $100.32 | 06/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809615427 | CMS |
| Actelion Pharmaceuticals US, Inc. | $23.09 | 06/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788002837 | CMS |
| JAZZ PHARMACEUTICALS INC. | $22.32 | 06/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845629517 | CMS |
| HARMONY BIOSCIENCES LLC | $8.33 | 06/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 853086047 | CMS |
| JAZZ PHARMACEUTICALS INC. | $19.61 | 06/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845627617 | CMS |
| JAZZ PHARMACEUTICALS INC. | $15.53 | 06/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845627615 | CMS |
| Janssen Pharmaceuticals, Inc | $13.56 | 06/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788002817 | CMS |
| GlaxoSmithKline, LLC. | $10.93 | 06/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802954499 | CMS |
| Insmed, Inc. | $26.82 | 06/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851726419 | CMS |
| NOVARTIS PHARMACEUTICALS CORPORATION | $13.39 | 06/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 815011531 | CMS |
| NOVARTIS PHARMACEUTICALS CORPORATION | $17.16 | 06/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 815011538 | CMS |
| E.R. Squibb & Sons, L.L.C. | $13.52 | 05/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783534685 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $462,347.37 | 124 |
| PY2024 | Principal investigator | $89,210.51 | 36 |
| PY2023 | Principal investigator | $147,626.44 | 41 |
| PY2022 | Principal investigator | $141,893.82 | 36 |
| PY2021 | Principal investigator | $67,525.35 | 23 |
| PY2020 | Principal investigator | $36,442.35 | 3 |
| PY2019 | Principal investigator | $47,535.40 | 7 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
124 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,737.50 | 12/17/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680760 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $127.60 | 12/17/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680762 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $325.00 | 12/17/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680764 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,577.81 | 12/11/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT | No dispute reported | 06/30/2026 | 1192144299 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.08 | 12/01/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680740 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.29 | 12/01/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680742 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $94.42 | 12/01/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680744 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $19,593.09 | 11/21/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | No dispute reported | 06/30/2026 | 1192183591 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $73.00 | 11/19/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680756 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $10.00 | 11/19/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680758 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,087.78 | 11/19/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU | No dispute reported | 06/30/2026 | 1192183566 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,740.00 | 11/19/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU | No dispute reported | 06/30/2026 | 1192183575 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,356.50 | 11/19/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU | No dispute reported | 06/30/2026 | 1192183586 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,712.50 | 11/19/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU | No dispute reported | 06/30/2026 | 1192183599 |
| Principal investigator 1 | Verona Pharma, Inc. | $647.33 | 11/19/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROU | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891783 |
| Principal investigator 1 | Verona Pharma, Inc. | $1,065.15 | 11/19/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROU | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891785 |
| Principal investigator 1 | Verona Pharma, Inc. | $990.00 | 11/19/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROU | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891787 |
| Principal investigator 1 | Verona Pharma, Inc. | $16,605.00 | 11/19/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROU | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891789 |
| Principal investigator 1 | Verona Pharma, Inc. | $900.00 | 11/19/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROU | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891791 |
| Principal investigator 1 | Verona Pharma, Inc. | $10,935.00 | 11/19/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROU | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891793 |
| Principal investigator 1 | Verona Pharma, Inc. | $540.00 | 11/19/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROU | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891795 |
| Principal investigator 1 | Verona Pharma, Inc. | $3,105.00 | 11/19/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROU | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891797 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $675.00 | 11/17/2025 | Non-covered Recipient Entity Horizon Clinical Research Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220814537 |
| Principal investigator 1 | Verona Pharma, Inc. | $62,586.68 | 11/14/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROU | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891751 |
| Principal investigator 1 | Verona Pharma, Inc. | $1,120.00 | 11/12/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROU | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891821 |
| Principal investigator 1 | Verona Pharma, Inc. | $6,090.00 | 11/12/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROU | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891823 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.29 | 11/01/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680734 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $94.42 | 11/01/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680736 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.08 | 11/01/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680738 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $233.20 | 10/27/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680746 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $401.50 | 10/27/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680748 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $13.92 | 10/27/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680750 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.65 | 10/27/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680752 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $15.00 | 10/27/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680754 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,841.99 | 10/24/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU | No dispute reported | 06/30/2026 | 1192183548 |
| Principal investigator 1 | PFIZER INC. | $143.30 | 10/24/2025 | Non-covered Recipient Entity HOUSTON PULMONARY SLEEP AND ALLERGY ASSOCIATESDBA TEXAS MULTISPECIALTY GROUP | AN INTERVENTIONAL PHASE 23 RANDOMIZED DOUBLEBLIND THIRD PARTYUNBLINDED PLACEBOCONTROLLED PARALLELGROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH MODERATETOSEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE COPD | No dispute reported | 06/30/2026 | 1228823550 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,767.84 | 10/23/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | No dispute reported | 06/30/2026 | 1192099776 |
| Principal investigator 1 | Verona Pharma, Inc. | $45,555.05 | 10/10/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROU | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891749 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,000.00 | 10/08/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | No dispute reported | 06/30/2026 | 1192181982 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $0.87 | 10/06/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680718 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.72 | 10/06/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680720 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $0.70 | 10/06/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680722 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $9.60 | 10/06/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680724 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.39 | 10/06/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680726 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,790.00 | 10/02/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192144288 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.29 | 10/01/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680728 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.08 | 10/01/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680730 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $94.42 | 10/01/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680732 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $81.62 | 09/24/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680710 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $109.50 | 09/24/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680712 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6.96 | 09/24/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680714 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $15.00 | 09/24/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680716 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $10,899.90 | 09/24/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | No dispute reported | 06/30/2026 | 1192183553 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,577.81 | 09/18/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT | No dispute reported | 06/30/2026 | 1192183561 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $16,757.84 | 09/17/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU | No dispute reported | 06/30/2026 | 1192099750 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,065.96 | 09/12/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU | No dispute reported | 06/30/2026 | 1192181986 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $8,436.46 | 09/10/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU | No dispute reported | 06/30/2026 | 1192181999 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.01 | 09/08/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680766 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.21 | 09/08/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680768 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.21 | 09/08/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680770 |
| Principal investigator 1 | PFIZER INC. | $2,181.60 | 09/07/2025 | Non-covered Recipient Entity HOUSTON PULMONARY SLEEP AND ALLERGY | AN INTERVENTIONAL PHASE 23 RANDOMIZED DOUBLEBLIND THIRD PARTYUNBLINDED PLACEBOCONTROLLED PARALLELGROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH MODERATETOSEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE COPD | No dispute reported | 06/30/2026 | 1228823529 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $16,301.36 | 09/03/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU | No dispute reported | 06/30/2026 | 1192133291 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,736.26 | 09/03/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | No dispute reported | 06/30/2026 | 1192183578 |
| Principal investigator 1 | Verona Pharma, Inc. | $16,500.00 | 09/03/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROU | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891667 |
| Principal investigator 1 | Verona Pharma, Inc. | $1,852.00 | 09/03/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROU | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891669 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $94.42 | 09/01/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680696 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.29 | 09/01/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680698 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.08 | 09/01/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680700 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $151.58 | 08/26/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680702 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $182.50 | 08/26/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680704 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $9.30 | 08/26/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680706 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $25.00 | 08/26/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680708 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $22,092.84 | 08/22/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | No dispute reported | 06/30/2026 | 1192181990 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,250.00 | 08/12/2025 | Non-covered Recipient Entity Horizon Clinical Research Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220814535 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $7,485.39 | 08/06/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU | No dispute reported | 06/30/2026 | 1192181974 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $94.42 | 08/01/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680690 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.08 | 08/01/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680692 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.29 | 08/01/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680694 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,973.00 | 08/01/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | No dispute reported | 06/30/2026 | 1192133256 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $27,640.00 | 08/01/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | No dispute reported | 06/30/2026 | 1192133270 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $978.18 | 07/25/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU | No dispute reported | 06/30/2026 | 1192099757 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,485.00 | 07/22/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT | No dispute reported | 06/30/2026 | 1192133264 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,037.50 | 07/22/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT | No dispute reported | 06/30/2026 | 1192133285 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,050.00 | 07/22/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT | No dispute reported | 06/30/2026 | 1192144295 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,383.72 | 07/18/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | No dispute reported | 06/30/2026 | 1192181994 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.29 | 07/01/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680684 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.08 | 07/01/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680686 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $94.42 | 07/01/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680688 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,396.17 | 06/20/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU | No dispute reported | 06/30/2026 | 1192099745 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $81.38 | 06/20/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU | No dispute reported | 06/30/2026 | 1192144283 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,000.00 | 06/06/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192183571 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.08 | 06/01/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680660 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.29 | 06/01/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680662 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $94.42 | 06/01/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680664 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $785.00 | 06/01/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680666 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 06/01/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680668 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 06/01/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680670 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $186.56 | 05/27/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680672 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $19.98 | 05/27/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680674 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $401.50 | 05/27/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680676 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $9.28 | 05/27/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680678 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $65.55 | 05/27/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680680 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $30.00 | 05/27/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680682 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,828.00 | 05/09/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192144303 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.08 | 05/01/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680654 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $94.42 | 05/01/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680656 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.29 | 05/01/2025 | Non-covered Recipient Entity Houston Pulmonary Sleep And Allergy Associates | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220680658 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,000.00 | 04/28/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU | No dispute reported | 06/30/2026 | 1192183539 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $15,158.56 | 04/24/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT | No dispute reported | 06/30/2026 | 1192099764 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,449.00 | 04/16/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192183557 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $10,642.89 | 04/09/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU | No dispute reported | 06/30/2026 | 1192099769 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,425.00 | 03/21/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU | No dispute reported | 06/30/2026 | 1192133243 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,397.50 | 03/21/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU | No dispute reported | 06/30/2026 | 1192133251 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,000.00 | 03/21/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192133279 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,712.50 | 03/21/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU | No dispute reported | 06/30/2026 | 1192144291 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,007.46 | 03/21/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU | No dispute reported | 06/30/2026 | 1192181970 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,493.40 | 03/21/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU | No dispute reported | 06/30/2026 | 1192181979 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,693.62 | 03/21/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU | No dispute reported | 06/30/2026 | 1192183535 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,973.00 | 03/21/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU | No dispute reported | 06/30/2026 | 1192183582 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $17,570.25 | 03/21/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU | No dispute reported | 06/30/2026 | 1192183595 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,537.23 | 02/24/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU | No dispute reported | 06/30/2026 | 1192099784 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $2,850.00 | 01/29/2025 | Non-covered Recipient Entity ACE CLINICAL RESEARCH GROUP | A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE) | No dispute reported | 06/30/2026 | 1185550757 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,971.25 | 01/09/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU | No dispute reported | 06/30/2026 | 1192183543 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $3,486.59 | 01/08/2025 | Non-covered Recipient Entity ACE CLINICAL RESEARCH GROUP | A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler | No dispute reported | 06/30/2026 | 1185550759 |